data
query
queries
{
"author": {
"name": "Paul Fortunato",
"webUrl": "/author/profile/paul-fortunato/",
"description": "",
"imageLarge": "https://secure.gravatar.com/avatar/f16d6fc2845f417ea0e93a3f2b6cd37d?s=136&d=mm&r=g",
"estimate": 2,
"social": [],
"articles": [
{
"uri": "/2023/06/29/specialty-drugs-employers-are-weary-and-for-good-reason/",
"title": "Specialty drugs: employers are weary (and for good reason)",
"byline": "Paul Fortunato",
"kicker": "",
"prettyDate": "June 29, 2023",
"timeToRead": "4 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2023/06/AdobeStock_119343831.jpg",
"width": "620",
"height": "372"
},
"authors": [
{
"webUrl": "/author/profile/paul-fortunato/",
"name": "Paul Fortunato"
}
],
"kickerNode": [],
"summary": "The specialty drug pipeline is evolving and contributing to rising costs. Over the last 10 years, the total specialty-drug market spend has approximately…",
"body": null
},
{
"uri": "/2022/07/05/how-self-insured-employers-can-mitigate-risk-in-the-face-of-a-strong-specialty-drug-pipeline/",
"title": "How self-insured employers can mitigate risk in the face of a strong specialty drug pipeline",
"byline": "Paul Fortunato",
"kicker": "",
"prettyDate": "July 05, 2022",
"timeToRead": "6 minute",
"image": {
"uri": "https://images.benefitspro.com/contrib/content/uploads/sites/412/2022/06/Prescription-drug-costs-Kenishirotie-at-AdobeStock.jpg",
"width": "617",
"height": "411"
},
"authors": [
{
"webUrl": "/author/profile/paul-fortunato/",
"name": "Paul Fortunato"
}
],
"kickerNode": [],
"summary": "It's imperative brokers and consultants help their self-insured clients get in front of issues before they arise.",
"body": null
}
]
}
}